Making an Impact with Novel Rapidly-Acting Agents in the Treatment of Major Depressive Disorder

Matthew Macaluso, DO


September 12, 2022

Matthew Macaluso, DO, recounts the transformation of a patient who was struggling with major depressive disorder and benefited from treatment with a novel rapidly-acting intranasal formulation of the drug esketamine.

Dr Macaluso notes the rapid and profound improvement over the course of a few weeks, which was visible to the resident attending Dr Macaluso — who did not even recognize the patient after treatment with esketamine. The emergence of novel rapidly-acting agents in the treatment landscape of patients with major depressive disorder truly represents a new and impactful approach.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.